Osteo-D15 ml

Osteo-D is a fat-soluble vitamin (vitamin D3) supplement used for the following indications:

Established/approved uses

• Prevention and treatment of vitamin D deficiency and insufficiency in infants, children, adults, and the elderly.
• Prevention and treatment of nutritional rickets in children and osteomalacia in adults.
• Adjunct (together with calcium) in the prevention and management of osteoporosis, particularly in postmenopausal women and elderly patients at risk of bone loss.

Guideline-supported / adjunct uses

• Supportive therapy in hypoparathyroidism and certain forms of renal osteodystrophy, usually as an adjunct to other agents and under specialist supervision.
• Correction of vitamin D deficiency in malabsorption syndromes (e.g. celiac disease, inflammatory bowel disease, post-bariatric surgery) as part of overall nutritional management.

Osteo-D is not an antibiotic and has no role in treating infections.

Colecalciferol [Vitamin D3] contains cholecalciferol (vitamin D3) as the active ingredient. It is available locally in several dosage forms and strengths, including tablets, capsules (including high-strength weekly/monthly capsules), oral solution/drops, and an injectable (oral/IM) solution, so the exact strength should be confirmed on the product label.

Osteo-D is the naturally occurring form of vitamin D, a fat-soluble secosteroid that is synthesized in the skin on exposure to ultraviolet-B sunlight and is also obtained from the diet and supplements. It is metabolized in the liver to 25-hydroxyvitamin D and then in the kidney to the active hormone calcitriol (1,25-dihydroxyvitamin D), which regulates calcium and phosphate homeostasis.

Osteo-D is used clinically to prevent and correct vitamin D deficiency, support bone mineralization, and reduce the risk of metabolic bone disease when dietary intake or sunlight exposure is insufficient.

Fat-soluble vitamin; Vitamin D and its analogues (Osteo-D)

Colecalciferol [Vitamin D3] (cholecalciferol) is biologically inactive until it undergoes two sequential hydroxylation steps: first in the liver to 25-hydroxyvitamin D (calcifediol), and then in the kidney to the active metabolite 1,25-dihydroxyvitamin D (calcitriol).

Calcitriol acts on vitamin D receptors in the intestine, bone, kidney, and parathyroid glands to:

• Increase intestinal absorption of dietary calcium and phosphate.
• Promote renal tubular reabsorption of calcium.
• Regulate osteoblast/osteoclast activity to support normal bone mineralization and remodeling.
• Suppress parathyroid hormone (PTH) secretion, helping maintain calcium homeostasis.

Vitamin D receptors are also present in immune and other tissues, and Colecalciferol [Vitamin D3] contributes to normal immune and muscular function, though these effects are secondary to its established role in calcium/phosphate and bone metabolism.

Osteo-D tablets and capsules should be swallowed with a glass of water, preferably with a meal containing some fat to enhance absorption, since vitamin D is fat-soluble. Oral solution/drops should be measured using the dropper or measuring device provided and can be given directly or mixed with food/formula for infants. The injectable form of Osteo-D is administered by a healthcare professional (oral or intramuscular route as labeled) and should not be self-administered.

Do not take more than the prescribed dose or frequency of Osteo-D, especially with high-strength weekly or monthly products, as doses are cumulative.

• Thiazide diuretics: concurrent use with Osteo-D can increase the risk of hypercalcemia by reducing urinary calcium excretion; calcium levels should be monitored.
• Digoxin and other cardiac glycosides: Osteo-D-induced hypercalcemia can potentiate digoxin toxicity and precipitate cardiac arrhythmias; calcium should be monitored closely in patients on digoxin.
• Phenytoin, phenobarbital, and other enzyme-inducing anticonvulsants: may accelerate hepatic metabolism of vitamin D, reducing the effectiveness of Osteo-D and increasing dose requirements.
• Systemic corticosteroids: can impair calcium absorption and vitamin D metabolism, reducing the effect of Osteo-D.
• Cholestyramine, colestipol, orlistat, and mineral oil: reduce intestinal absorption of fat-soluble Osteo-D; doses should be separated in time where co-administration is necessary.
• Ketoconazole and other azole antifungals: can inhibit enzymes involved in vitamin D activation and degradation, altering calcitriol levels.
• Calcium supplements or calcium-containing antacids: concomitant high-dose use with Osteo-D increases the risk of hypercalcemia.

At recommended doses, Osteo-D is generally well tolerated. Reported adverse effects include:

• Gastrointestinal: nausea, vomiting, abdominal pain/cramping, constipation, decreased appetite.
• General: headache, fatigue, mild allergic reactions (rash, pruritus) rarely.

With excessive or prolonged high-dose use, hypercalcemia can occur (see Overdose Effects and Precautions and Warnings for details and symptoms) — this is a dose-related toxicity rather than a typical side effect at recommended intake.

Osteo-D at doses that do not exceed the recommended dietary allowance is generally considered safe in pregnancy and is often recommended to maintain adequate maternal vitamin D status. At doses above the recommended allowance, safety data are more limited, so Osteo-D should be used in pregnancy only as directed by a physician, with the dose individualized to actual need; avoid unsupervised high-dose regimens.

Vitamin D and its metabolites are excreted in breast milk in proportion to maternal vitamin D status. Osteo-D taken by a breastfeeding mother at recommended doses is generally considered compatible with breastfeeding; a physician should be consulted regarding the mother's dose and whether the breastfed infant also needs separate vitamin D supplementation.

Use Osteo-D with caution and periodic monitoring of serum calcium (and, where relevant, 25-hydroxyvitamin D) in the following situations:

• High-dose or prolonged supplementation, where cumulative intake can lead to vitamin D toxicity and hypercalcemia (see Overdose Effects).
• Granulomatous disorders (e.g. sarcoidosis, tuberculosis) and certain lymphomas, in which extra-renal conversion to active vitamin D can be increased, raising the risk of hypercalcemia even at ordinary doses.
• Renal impairment, where vitamin D metabolism is altered and calcium/phosphate monitoring is needed.
• Hepatic impairment, which can reduce activation of Osteo-D to its active metabolites.
• Concurrent use with digoxin or thiazide diuretics (see Interactions).
• Immobilized patients or those with pre-existing hypercalciuria, who are at greater risk of hypercalcemia/hypercalciuria on supplementation.

Do not exceed the recommended dose of Osteo-D without medical advice, and do not combine multiple vitamin D-containing products without checking cumulative daily intake.

Overdose or prolonged excessive intake of Osteo-D can cause vitamin D toxicity with hypercalcemia. Early symptoms may include weakness, fatigue, headache, dry mouth, metallic taste, nausea, vomiting, constipation, and muscle or bone pain. More severe or prolonged toxicity can cause polyuria, polydipsia, dehydration, confusion, cardiac arrhythmias, and impaired kidney function, including nephrocalcinosis.

If overdose of Osteo-D is suspected, discontinue the product and seek immediate medical attention or contact a poison control center/emergency services; treatment (which may include stopping supplemental calcium and vitamin D, IV fluids, and other supportive measures) should be managed by a physician. Do not attempt to treat suspected overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: Patients with chronic kidney disease have reduced capacity to convert Osteo-D to its active metabolite and are at higher risk of disturbed calcium/phosphate balance; dosing should be individualized and calcium/phosphate monitored, generally under specialist (nephrology) supervision.

Hepatic impairment: Hepatic hydroxylation of Osteo-D may be reduced; monitor response and consider alternative activated vitamin D analogues if clinically indicated.

Elderly: Commonly used for deficiency prevention/treatment and osteoporosis prevention; no specific dose reduction is generally required, but calcium levels should be monitored with high-dose regimens, especially with concurrent thiazides or digoxin.

Obesity: Vitamin D is sequestered in body fat, and obese patients may require higher doses of Osteo-D to achieve and maintain adequate serum 25(OH)D levels.

Malabsorption syndromes: Patients with fat malabsorption (e.g. celiac disease, cystic fibrosis, post-bariatric surgery, inflammatory bowel disease) may require higher or parenteral doses of Osteo-D due to reduced enteral absorption.

Duration of Osteo-D therapy depends on the indication: deficiency-treatment regimens are typically given for a defined course (commonly 6-8 weeks) followed by reassessment of serum 25-hydroxyvitamin D and, if needed, a switch to a lower maintenance dose. Maintenance or preventive supplementation, and use as an adjunct in osteoporosis, is generally continued long-term/indefinitely under periodic medical review, particularly if risk factors for deficiency persist.

Vitamin D analogues / Fat-soluble vitamins (Colecalciferol [Vitamin D3])

Colecalciferol [Vitamin D3] (cholecalciferol) is hydroxylated in the liver to 25-hydroxyvitamin D and then in the kidney to the active hormone calcitriol (1,25-dihydroxyvitamin D). Calcitriol binds nuclear vitamin D receptors to increase intestinal calcium and phosphate absorption, promote renal calcium reabsorption, and regulate bone remodeling, thereby correcting deficiency states and supporting normal bone mineralization.

Category A (at doses not exceeding the recommended dietary allowance); Category C at doses exceeding the recommended dietary allowance (FDA legacy pregnancy category system).

Osteo-D is widely used in infants and children for prevention and treatment of vitamin D deficiency and rickets. The American Academy of Pediatrics recommends 400 IU/day of vitamin D for exclusively and partially breastfed infants beginning in the first days of life, continued until the infant is weaned to at least 1 liter/day of vitamin D-fortified formula or milk, and 600 IU/day for older children and adolescents who do not obtain adequate intake from diet.

Higher-strength weekly or monthly Osteo-D capsules used for adult deficiency treatment are generally not appropriate for infants and young children; low-strength drops/oral solution dosed by a healthcare provider should be used instead. Safety and efficacy of specific high-dose products in neonates and infants have not been separately established, and dosing in this age group should always be individualized by a pediatrician.